Physician
Bon Secours ST. Francis Xavier Hospital INC.
Bon Secours ST. Francis Xavier Hospital INC. was paid $35.85M by Medicaid between Jan 2018 and Dec 2024, across 282 billing codes. Its largest line is J7050, Infusion, normal saline solution, 250 cc — 12% of everything it billed.
33Billing provider infoBON SECOURS ST. FRANCIS XAVIER HOSPITAL INC.
CHARLESTON, SC 29414
CHARLESTON, SC 29414
33aNPI1851361778assigned 01/24/2006
33bProvider typeCritical Care Medicine (Internal Medicine) Physician
28Total paid$35.85M
24GClaims611,085
24DCodes billed282
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Care Medicine (Internal Medicine) Physician providers in South Carolina
Rank by total paid#1 of 17
Median peer was paid$68K
This provider vs. median526×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 75,383 | $2.42M | |
| 2019 | 71,742 | $2.58M | |
| 2020 | 63,098 | $3.19M | |
| 2021 | 77,045 | $4.05M | |
| 2022 | 75,731 | $5.53M | |
| 2023 | 126,125 | $11.49M | |
| 2024incomplete | 121,961 | $6.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7050 | Infusion, normal saline solution, 250 cc | 12% | 4,070 | 2,210 | $4.41M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 8.3% | 10,184 | 8,119 | $2.97M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 7.8% | 6,576 | 3,661 | $2.80M |
| J3490 | Unclassified drugs | 7.4% | 2,067 | 1,158 | $2.66M |
| 80053 | Comprehensive metabolic panel | 5.6% | 29,921 | 25,103 | $2.01M |
| 36415 | Collection of venous blood by venipuncture | 5.1% | 22,484 | 18,175 | $1.84M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.5% | 27,275 | 24,767 | $1.61M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 14,991 | 13,076 | $1.14M |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.8% | 17,228 | 14,740 | $1.02M |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 2.6% | 504 | 490 | $930K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 8,559 | 5,611 | $786K |
| 81001 | 2.1% | 12,579 | 11,366 | $766K |
270 more codes
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 2.0% | 945 | $706K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.9% | 4,905 | $692K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.8% | 3,233 | $654K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 4,423 | $590K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.5% | 4,768 | $554K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 2,796 | $512K |
| 81003 | 1.3% | 11,555 | $480K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.3% | 3,884 | $474K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 15,264 | $434K |
| 99284 | Emergency room visit (serious) | <1% | 25,503 | $355K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,258 | $297K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,853 | $289K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,232 | $287K |
| 96402 | <1% | 688 | $280K | |
| 81025 | <1% | 10,062 | $270K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,189 | $250K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 580 | $226K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,045 | $202K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,246 | $200K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,394 | $189K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,208 | $175K |
| 86901 | <1% | 4,066 | $167K | |
| 93971 | <1% | 1,210 | $165K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,040 | $159K |
| 87210 | <1% | 1,526 | $141K | |
| 84702 | <1% | 3,572 | $141K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,597 | $137K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 148 | $133K |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 391 | $129K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,488 | $124K |
| 71250 | <1% | 737 | $122K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,873 | $120K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 168 | $119K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 749 | $117K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,433 | $110K |
| 87430 | <1% | 1,903 | $105K | |
| 99285 | Emergency room visit (most serious) | <1% | 13,306 | $104K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,968 | $103K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,173 | $102K |
| 85027 | <1% | 17,503 | $101K | |
| 59025 | Fetal non-stress test | <1% | 2,315 | $99K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,688 | $95K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,435 | $95K |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 125 | $91K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,543 | $82K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,576 | $79K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,598 | $78K |
| 73630 | <1% | 1,013 | $72K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,517 | $66K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,557 | $66K |
| 72100 | <1% | 1,492 | $58K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,030 | $56K |
| 73562 | <1% | 803 | $53K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 644 | $51K |
| 73610 | <1% | 638 | $48K | |
| 73030 | <1% | 926 | $48K | |
| 84484 | <1% | 8,497 | $47K | |
| 87040 | <1% | 2,456 | $45K | |
| 72141 | <1% | 68 | $44K | |
| 87428 | <1% | 209 | $42K | |
| 82728 | <1% | 3,031 | $39K | |
| 76830 | Ultrasound, transvaginal | <1% | 869 | $37K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,595 | $35K |
| 62323 | <1% | 556 | $32K | |
| 86850 | <1% | 2,701 | $32K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 788 | $29K |
| 80076 | <1% | 3,411 | $29K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,439 | $28K |
| 84132 | <1% | 894 | $27K | |
| 72050 | <1% | 331 | $26K | |
| 96401 | <1% | 68 | $25K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 681 | $25K |
| 76825 | <1% | 236 | $25K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 644 | $24K |
| 73221 | <1% | 38 | $23K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 495 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,508 | $22K |
| 82607 | <1% | 1,441 | $21K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 436 | $21K |
| 77300 | <1% | 13 | $21K | |
| G0378 | Hospital observation service, per hour | <1% | 3,910 | $21K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 685 | $21K |
| 84439 | <1% | 1,935 | $20K | |
| 76642 | <1% | 539 | $19K | |
| 76820 | <1% | 1,899 | $19K | |
| 77066 | Tomosynthesis, mammo | <1% | 168 | $18K |
| 96367 | <1% | 2,528 | $18K | |
| 73130 | <1% | 239 | $18K | |
| 96376 | <1% | 3,617 | $18K | |
| 85610 | <1% | 3,395 | $16K | |
| 73502 | <1% | 463 | $16K | |
| 84112 | <1% | 47 | $15K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 233 | $14K |
| 84703 | <1% | 224 | $13K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 118 | $13K |
| 73560 | <1% | 350 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,541 | $11K |
| 76536 | <1% | 123 | $10K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 152 | $10K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 417 | $10K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 785 | $10K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,005 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,029 | $9K |
| 77336 | <1% | 69 | $9K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 132 | $9K |
| 97161 | <1% | 954 | $8K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,925 | $8K |
| 93976 | <1% | 405 | $8K | |
| C1769 | Guide wire | <1% | 61 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,856 | $8K |
| 73110 | <1% | 116 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 43 | $7K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 44 | $7K |
| 86900 | <1% | 3,887 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $6K |
| 82570 | <1% | 1,677 | $6K | |
| 84156 | <1% | 1,548 | $6K | |
| 83605 | <1% | 4,624 | $5K | |
| 87077 | <1% | 1,839 | $5K | |
| A9270 | Non-covered item or service | <1% | 5,691 | $5K |
| 93970 | <1% | 25 | $5K | |
| 74019 | <1% | 314 | $5K | |
| 80061 | Lipid panel | <1% | 2,854 | $5K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 186 | $5K |
| 0240U | <1% | 28 | $4K | |
| 83735 | <1% | 4,663 | $4K | |
| 85379 | <1% | 2,286 | $3K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $3K |
| 86592 | <1% | 872 | $3K | |
| 82746 | <1% | 959 | $3K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 13 | $3K |
| 74018 | <1% | 116 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 43 | $2K |
| 96523 | <1% | 100 | $2K | |
| 87807 | <1% | 196 | $2K | |
| 82950 | <1% | 756 | $2K | |
| 82378 | <1% | 495 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 41 | $2K |
| 83880 | <1% | 2,785 | $2K | |
| 83520 | <1% | 791 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 672 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 38 | $1K |
| 88304 | <1% | 98 | $1K | |
| 83021 | <1% | 159 | $1K | |
| 12001 | <1% | 14 | $1K | |
| 72072 | <1% | 25 | $1K | |
| 86140 | <1% | 603 | $1K | |
| 97162 | <1% | 103 | $979.48 | |
| 87486 | <1% | 12 | $964.33 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 186 | $962.90 |
| 82105 | <1% | 220 | $899.10 | |
| 36430 | <1% | 129 | $873.98 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 103 | $772.15 |
| 82784 | <1% | 84 | $638.15 | |
| 83690 | <1% | 9,055 | $525.49 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 874 | $521.22 |
| 84153 | <1% | 125 | $505.68 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,020 | $495.65 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,075 | $480.50 |
| 86803 | <1% | 247 | $434.41 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,462 | $413.91 |
| 82550 | <1% | 1,689 | $383.32 | |
| 86300 | <1% | 90 | $353.44 | |
| 96415 | <1% | 1,833 | $321.67 | |
| 83540 | <1% | 1,904 | $294.19 | |
| 83615 | <1% | 624 | $287.09 | |
| 76821 | <1% | 343 | $272.34 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,599 | $204.70 |
| 85045 | <1% | 804 | $196.98 | |
| 86780 | <1% | 119 | $163.57 | |
| 84165 | <1% | 72 | $149.75 | |
| 83550 | <1% | 1,807 | $140.22 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 209 | $129.48 |
| 87070 | <1% | 74 | $121.06 | |
| 0098U | <1% | 21 | $115.45 | |
| 96368 | <1% | 842 | $105.34 | |
| 97165 | <1% | 50 | $92.21 | |
| 90686 | <1% | 42 | $59.01 | |
| 85652 | <1% | 334 | $54.42 | |
| 83970 | <1% | 12 | $54.27 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 153 | $42.21 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,396 | $38.81 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,717 | $32.94 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 591 | $32.08 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 68 | $31.79 |
| 85018 | <1% | 106 | $25.62 | |
| 85730 | <1% | 1,081 | $15.79 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,020 | $12.86 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 734 | $10.98 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,262 | $10.98 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 696 | $10.76 |
| 84100 | <1% | 347 | $2.71 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 35 | $1.47 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 2,075 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,172 | $0.00 |
| 87340 | 0% | 1,099 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 379 | $0.00 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 0% | 480 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 78 | $0.00 |
| 96411 | 0% | 474 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 164 | $0.00 |
| 86762 | 0% | 478 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 463 | $0.00 |
| 88342 | 0% | 280 | $0.00 | |
| J9045 | Injection, carboplatin, 50 mg | 0% | 385 | $0.00 |
| 86706 | 0% | 13 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 198 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,353 | $0.00 |
| 88307 | 0% | 72 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 290 | $0.00 |
| 82803 | 0% | 61 | $0.00 | |
| 86747 | 0% | 336 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 26 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 198 | $0.00 |
| 85660 | 0% | 172 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 99 | $0.00 |
| J0185 | Injection, aprepitant, 1 mg | 0% | 33 | $0.00 |
| 86920 | 0% | 163 | $0.00 | |
| J9395 | Injection, fulvestrant, 25 mg | 0% | 18 | $0.00 |
| 82043 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 21 | $0.00 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 31 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 34 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 31 | $0.00 |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 27 | $0.00 |
| 87205 | 0% | 29 | $0.00 | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 0% | 16 | $0.00 |
| 82677 | 0% | 13 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 12 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 32 | $0.00 |
| 87581 | 0% | 12 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 13 | $0.00 |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 119 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 33 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 992 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 121 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 679 | $0.00 |
| J9271 | Injection, pembrolizumab, 1 mg | 0% | 675 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 206 | $0.00 |
| 87186 | 0% | 827 | $0.00 | |
| 84145 | 0% | 696 | $0.00 | |
| 90715 | 0% | 165 | $0.00 | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 0% | 268 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 242 | $0.00 |
| 96417 | 0% | 1,582 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 17 | $0.00 |
| J0897 | Injection, denosumab, 1 mg | 0% | 166 | $0.00 |
| J9206 | Injection, irinotecan, 20 mg | 0% | 299 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 352 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 92 | $0.00 |
| 93017 | 0% | 13 | $0.00 | |
| 86787 | 0% | 129 | $0.00 | |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 997 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 99 | $0.00 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 341 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 1,067 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 175 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 102 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 72 | $0.00 |
| 84550 | 0% | 15 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 36 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 68 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 14 | $0.00 |
| 99215 | Doctor's office visit, returning patient (complex) | 0% | 13 | $0.00 |
| 86336 | 0% | 13 | $0.00 | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 0% | 76 | $0.00 |
| 82947 | 0% | 12 | $0.00 | |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 17 | $0.00 |
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified | 0% | 15 | $0.00 |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, BRET (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Roper Hospital, INC | Charleston, SC | $22.01M |
| Bret M. Johnson DDS MS PS | Spokane, WA | $1.23M |
| Roper ST Francis Hospital-Berkeley INC. | Summerville, SC | $661K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.